Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02579811 · ClinicalTrials.gov registry record · Phase 2
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
A Phase 2 study of Metastatic Renal Cell Cancer, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT02579811 is a Phase 2 study of Metastatic Renal Cell Cancer that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 40 participants, below the 52-participant average among 6 other Metastatic Renal Cell Cancer trials with a reported enrollment target (23% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT02579811, a Phase 2 study of Metastatic Renal Cell Cancer, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
Axitinib is a drug which is approved by the FDA for patients with advanced kidney cancer who have already received some treatment. It works by reducing blood flow to a tumor. Axitinib is normally give at 5mg twice per day and sometimes this dose is increased if patients tolerate it. The purpose of this study is to figure out a different way to decide which dose of axitinib each patient should receive based on the side effects they experience.
Conditions Studied
Interventions
- DRUG Axitinib
Study Locations (4)
Ohio
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland
- The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute - Columbus
California
- City of Hope Comprehensive Cancer Center - Duarte
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-12-30 |
| Est. Completion | 2023-06-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02579811
The ClinicalTrials.gov registry entry for NCT02579811 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 52-participant average among 6 other Metastatic Renal Cell Cancer trials with a reported enrollment target (23% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Renal Cell Cancer appearing as the primary indexed condition, and to 1 intervention - of which Axitinib is the first listed.
NCT02579811 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Ohio, California, Tennessee.
Frequently Asked Questions
What is clinical trial NCT02579811 about?
NCT02579811 is a clinical study titled "Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer". Axitinib is a drug which is approved by the FDA for patients with advanced kidney cancer who have already received some treatment. It works by reducing blood flow to a tumor. Axitinib is normally give at 5mg twice per day and sometimes this dose is increased if patients tolerate it. The purpose of t...
What is the current status of trial NCT02579811?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2015-12-30. Estimated completion is 2023-06-20.
What conditions does trial NCT02579811 study?
This clinical trial studies the following conditions: Metastatic Renal Cell Cancer.
What interventions are being tested in trial NCT02579811?
The interventions under investigation include: Axitinib (DRUG).
Who is sponsoring clinical trial NCT02579811?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02579811 being conducted?
This trial has 4 study locations across California, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Renal Cell Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
-
18F-FSPG PET/CT for Cancer Patients on Therapy
COMPLETED · Phase 2
-
Aerosolized Aldesleukin in Treating Patients With Lung Metastases
ACTIVE NOT RECRUITING · Phase 1
-
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
ACTIVE NOT RECRUITING
-
Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer
COMPLETED · Early Phase 1
-
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.